Association between APOE e4 and white matter hyperintensity volume, but not total brain volume or white matter integrity

Donald M. Lyall 1 · Simon R. Cox 2 · Laura M. Lyall 1 · Carlos Celis-Morales 3 · Breda Cullen 1 · Daniel F. Mackay 1 · Joey Ward 1 · Rona J. Strawbridge 1,4 · Andrew M. McIntosh 5 · Naveed Sattar 3 · Daniel J. Smith 1 · Jonathan Cavanagh 1 · Ian J. Deary 2 · Jill P. Pell 1

Published online: 22 March 2019 © The Author(s) 2019

Abstract
Apolipoprotein (APOE) e4 genotype is an accepted risk factor for accelerated cognitive aging and dementia, though its neurostructural substrates are unclear. The deleterious effects of this genotype on brain structure may increase in magnitude into older age. This study aimed to investigate in UK Biobank the association between APOE e4 allele presence vs. absence and brain imaging variables that have been associated with worse cognitive abilities; and whether this association varies by cross-sectional age. We used brain magnetic resonance imaging (MRI) and genetic data from a general-population cohort: the UK Biobank (N = 8395 after exclusions). We adjusted for the covariates of age in years, sex, Townsend social deprivation scores, smoking history and cardiometabolic diseases. There was a statistically significant association between APOE e4 genotype and increased (i.e. worse) white matter (WM) hyperintensity volumes (standardised beta = 0.088, 95% confidence intervals = 0.036 to 0.139, P = 0.001), a marker of poorer cerebrovascular health. There were no associations with left or right hippocampal, total grey matter (GM) or WM volumes, or WM tract integrity indexed by fractional anisotropy (FA) and mean diffusivity (MD). There were no statistically significant interactions with age. Future research in UK Biobank utilising intermediate phenotypes and longitudinal imaging hold significant promise for this area, particularly pertaining to APOE e4’s potential link with cerebrovascular contributions to cognitive aging.

Keywords Aging · APOE · Epidemiology · Genetic association studies · MRI

Introduction
Variation at the APOE genetic locus is an established risk factor for Alzheimer’s disease (AD) (Lutz et al. 2010), and cognitive decline in domains of memory, information processing speed and overall cognitive function (“g”) (Wisdom et al. 2011). The e4 allele, which typically has a frequency of around 15% in Caucasian/European populations (Eisenberg et al. 2010), is known as the ‘risk’ allele, vs. the neutral e3 allele (typical frequency 78%) and possibly protective e2 allele (frequency 6%). The APOE locus’s main function relates to lipid/cholesterol metabolism, which is pleiotropic for several biological functions including neuronal migration, axon guidance, and the clearance of amyloid beta plaques – which characterise AD - in the brain (Holtzman et al. 2012).

There is evidence that the effects of APOE e4 variation on brain functioning increase across the lifespan, i.e. differences between e4 carriers vs. non-carriers in terms of cognitive ability become more pronounced with older age regardless of outright dementia (Schiepers et al. 2011). Davies et al. (2015) reported
data from the CHARGE consortium where in 53,949 European participants from 31 different cohorts (aged >45 years and non-demented), the strength of association between rs10119 (in the APOE genetic region) and a general factor of fluid cognitive function, increased linearly with the mean age of each cohort (Pearson’s r = −0.42, P = 0.022). Similarly, a report that included data from the Generation Scotland cohort (Marioni et al. 2015) (n = 18,337) reported significant negative associations between APOE e4 allele presence and tests scores on Logical memory (standardized beta = −0.095, P = 0.003), and Digit symbol coding (standardized beta = −0.087, P = 0.004); however this was only significant in participants aged 60 years or over. We recently investigated potential APOE e4 genotype-by-age interaction on cognitive function in UK Biobank (n = ~111 k) (Lyall et al. 2016b); there were no statistically significant interactions; however there are concerns over the potential imprecision and reliability in the novel UK Biobank baseline cognitive tests (Lyall et al. 2016a), which means that result may be an underestimate of the potential true effect. Overall, recent research warrants further study into the potential structural brain substrates of the APOE e4 effect into older age.

It is important to understand the neurobiological underpinnings of the potential age-related deleterious effects of APOE e4 on brain function. The integrity of connective WM tracts in the brain is associated with overall cognitive function (Penke et al. 2012). The hippocampus is a known brain substrate of memory loss, one of the key symptoms of AD, and is the first site to show evidence of amyloid beta plaques (Reilly et al. 2003). Total brain volumes, including total GM and WM volumes are significantly associated with changes in cognitive function (Royle et al. 2013). Brain WM hyperintensities are a major substrate of age-related cognitive decline and cerebrovascular disease (Debette and Markus 2010), and common in AD (Paternoster et al. 2009).

Investigating associations between APOE genotype and MRI markers is a topic of intense research, but studies using structural neuroimaging parameters have not produced consistent results (Scarmeas and Stern 2006). Whereas e4 carriers appear to be at increased risk of hippocampal atrophy (Manning et al. 2014), worse WM microstructural integrity (Slattery et al. 2017) and selective GM atrophy (Pievani et al. 2009) in the context of pathological aging (such as AD and mild cognitive impairment), there is less clarity with respect to MRI markers in non-pathological aging. For example, null associations are reported for APOE genotype and cross-sectional hippocampal volume (Ferencz et al. 2013; Jack et al. 1998; Killiany et al. 2002; Lyall et al. 2013; Manning et al. 2014; Schuff et al. 2009), brain atrophy (Cherbuin et al. 2008), GM volume (Cherbuin et al. 2008) and some WM measures (Lyall et al. 2014, 2015), though APOE e4 carriers exhibited greater WM hyperintensity growth over a 3-year period in older age when compared to non-e4 carriers (Cox et al. 2017). A meta-analysis (n = 8917) reported that e4 genotype is associated with greater burden of MRI markers associated with cerebrovascular disease (cerebral microbleeds (Schilling et al. 2013)). However, many prior studies possess low statistical power with which to detect subtle effects specifically in mid- and later-life, and thus it is unclear whether APOE status is unrelated to non-pathological brain aging, or whether subtler differences exist which prior studies have been unable to reliably quantify. It is possible on the other hand that APOE e4 has a stable association with poorer brain health which is not more pronounced in older age (Heise et al. 2011).

The UK Biobank cohort is a large prospective cohort of whom at the time of writing around 13,000 have genetic and MRI data (prior to exclusions). This report aims to test for an effect of APOE e4 genotype carrier status on specific brain imaging phenotypes in UK Biobank, and whether that association interacts with age. The large sample N improves the potential reliability of association estimates herein, compared with smaller reports as well as statistical power to detect small effects. We examined several specific brain imaging phenotypes based on a-priori hypotheses described above: left and right hippocampal volumes, total GM and WM volumes, WM hyperintensity volumes, and brain white matter tract integrity metrics.

It is hypothesized that for each brain phenotype, the association between APOE e4 genotype will be in the deleterious direction (i.e. lower scores for all except WM hyperintensity volumes and tract mean diffusivity, for which higher scores are worse), and interact with age where the association becomes larger in older participants (on average). We assessed the phenotypes of: two latent measures of WM tract integrity derived from tract-specific FA (‘gFA’ and MD (‘gMD’); total GM; total WM; total WM hyperintensity volume and hippocampal volumes (all volumes in millimetres$^3$). This will enable us to quantify, with considerable statistical power whether the effect of APOE e4 genotype on brain phenotypes of relevance to cognitive decline and AD is stronger in older age.

**Methods**

**Study design and participants**

The UK Biobank cohort is a large prospective cohort of 502,628 participants with phenotypic information. All participants attended one of 22 assessment centres from 2006 to 2010 where they completed a series of physical, sociodemographic, and medical assessments (Sudlow et al. 2015). In 2014, MRI scanning of baseline participants began, and this is ongoing until around 100,000 participants have been scanned. As of November 2017, n = 12,931 have MRI data derived by UK Biobank.

**Genetic data**

UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom array for ~50,000 participants and
of eigenvalues showed clear single unrotated factor solutions for gFA (eigenvalue = 12.83, $r^2 = 58\%$) and gMD (eigenvalue = 13.76, $r^2 = 63\%$). All brain MRI metrics were transformed into Z-scores based on the final analysis sample to ease interpretation.

**Covariates**

UK Biobank derived a Townsend deprivation score for all participants immediately prior to baseline; calculated from data on car ownership, household overcrowding, owner-occupation and unemployment aggregated for postcodes of residence (Townsend 1998). Higher Townsend scores equate to higher levels of area-based socio-economic deprivation. Participants were asked during the baseline and MRI assessments about any previous or current cardiometabolic conditions that had been diagnosed by their doctor. Specifically, participants were asked whether their doctor had diagnosed each of myocardial infarction, angina, hypertension, diabetes or stroke (individually). We defined CHD as either myocardial infarction (MI) or angina. Smoking was classified as never, previous, or current smoker based on self-report; we simplified this into a binary ever (previous plus current) vs. never variable. We excluded participants that stated only ‘prefer not to answer’ for disease and smoking variables: less than 1% of the sample.

**Exclusions**

There were 12,662 participants with APOE e genotype and brain MRI data. We excluded participants with non-white British ancestry, self-report vs. genetic sex mismatch, putative sex chromosomal aneuploidy, excess heterozygosity, and missingness rate > 0.1. This left $n = 11,065$. We removed participants who reported a neurological condition at baseline or scan visit (~5%; Supplementary Table 1); the inclusion of participants for whom genotype frequencies of e2/e2, e2/e3 and e3/e3 collated; e2/e4 is usually removed because it has potentially risk and protective alleles (Wisdom et al. 2016; Penke et al. 2012; Telford et al. 2017). Inspection

An average of four years after initial recruitment, a subset of UK Biobank participants also underwent head MRI on the same scanner at a single site (Cox et al. 2016). The release of brain MRI data as of August 2017 is the subject of the current study. All brain imaging data used here was processed and quality checked by UK Biobank (Alfaro-Almagro et al. 2016; Miller et al. 2016) and available in the form of Imaging Derived Phenotypes (IDPs). Details on the UK Biobank imaging acquisition and processing including WM/GM and hippocampal segmentation, and on the WM diffusion processing, are freely available from three sources: the UK Biobank protocol: http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=2367 and documentation; http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=1977 and has been described elsewhere (Cox et al. 2016; Miller et al. 2016). The total WM and GM variables were segmented automatically using FAST (Zhang et al. 2001) and were normalised for skull size based on the T1 MR scan (see open-access MRI protocol, pp.11; https://biobank.ctsu.ox.ac.uk/crystal/docs/brain_mri.pdf). Total WM hyperintensity volumes were calculated based on T1 and T2 FLAIR, derived by UK Biobank using the Brain Intensity Abnormality Classification Algorithm (BIANCA) (Griffanti et al. 2016) with the procedure detailed by Miller et al. (2016). WM hyperintensity volumes were log-transformed because it has potentially risk and protective alleles (Wisdom et al. 2016; Penke et al. 2012; Telford et al. 2017). Inspection

FA and MD are commonly-derived WM tract integrity variables which describe the directional coherence and magnitude of water molecule diffusion, respectively. Water molecules tend to diffuse with greater directional coherence and lower magnitude when constrained by tightly-packed fibres (such as well-myelinated axons) as well as by cell membranes, microtubules and other structures; lower FA and higher MD are generally considered to reflect poorer/less ‘healthy’ white matter (Jones et al. 2013). We constructed general factors of FA (gFA) and MD (gMD) using principal components analysis based on 22 tracts (Cox et al. 2016). These general measures reflect the high degree of shared microstructural properties across major white matter tracts in the brain; as found in this cohort, and various other groups (Alloza et al. 2016; Cox et al. 2016; Penke et al. 2012; Telford et al. 2017). Inspection
et al. 2011). We elected for an e4 dominant (i.e. present vs. absent) rather than dose model (i.e. 0/1/2) because there were relatively few e4 homozygotes. We ran two linear regression models to examine associations between e4 genotype and each of the brain imaging parameters: gFA scores, gMD scores, left/right hippocampal volume, total GM, total WM and log WM hyperintensity volumes in mm 3, each transformed to Z-scores. For the ‘partially adjusted model’ we adjusted for age, genetic array, 8 principal components (PCs) and sex. (The PCs were added conservatively to account for possible population stratification, although this made no difference to the results in terms of APOE e4). For the ‘fully adjusted model’ we then additionally adjusted for Townsend deprivation scores, ever vs. never smoking cigarettes, and self-reported doctor diagnosis of diabetes, hypertension and CHD. For interaction models we added the requisite e4*age interaction term. Finally, we re-ran analyses with added age 2 and an e4*age 2 interaction term to capture potentially curvilinear relationships.

We determined an alpha level of \( P < 0.05 \) as nominal significance, and corrected for multiple comparisons with the false discovery rate (FDR) using a specialized program (Pike 2011). We calculated statistical power using G*power 3 (Faul et al. 2007). We conducted two additional post-hoc sensitivity analyses: firstly, we adjusted for X/Y/Z-coordinates of brain position during scanning, because it was available in only \( n = 6647 \) participants. Secondly, we adjusted the final results for baseline assessment centre (one of 22 across the United Kingdom), to reduce the possibility of any systematic procedural differences e.g. handling of blood samples (although note that the MRI scanning data we report on here was single-site). A significant effect of e4 allele presence vs. absence would indicate mean level differences in the brain parameter of interest as a function of APOE e genotype (vs. absence) cross-sectionally. A significant interaction with age (or age 2) would be consistent with a hypothesis of greater (i.e. accelerating) decline with increasing age, according to APOE e4 allele presence vs. absence.

**Results**

Descriptive statistics are shown in Table 1, including chi square (for ordinal/categorical data) and ANOVA (for continuous data) tests of differences between APOE e4 presence vs. absence groups. There were 8395 participants (mean age = 61.55, SD = 7.03, range = 46–73), of whom 3953 were male (46.1%). G*Power 3 showed we had 99% power to find a standardised effect size of Cohen’s \( d = 0.1 \) (where 0.2 is considered small) for significant associations or interactions, based on our e4 present vs. absent sample sizes.

There were no associations between APOE e4 and gFA, gMD (Table 2), left/right hippocampal volumes, total GM or total WM both normalised for skull size: indicating no mean-level difference in these brain parameters across the sample. There was a significant association between APOE e4 possession and greater WM hyperintensity volume (fully-adjusted standardised beta = 0.088, 95% CI = 0.036 to 0.139, \( P = 0.001 \). There were no significant e4*cross-sectional age interactions at \( P < 0.05 \). Results were unchanged when we added an age 2 term (i.e. non-linear), adjusted for X/Y/Z-coordinates of brain position during MRI scanning, or baseline assessment centre. The e4 allele present vs. absent association was generally similar when we additionally corrected the WM hyperintensity volumes for total brain volume (total raw GM plus total raw WM): fully-adjusted standardised beta = 0.083, 95% CIs = 0.032 to 0.134, \( P = 0.001 \). Note that Table 1 shows a significant difference between e4 absent vs. present in terms of total GM (\( P = 0.002 \)), although this did not survive correction for relevant confounders (e.g. age and sex; see Table 2).

As additional exploratory analyses, we analysed the 22 individual tract-specific FA/MD values identified as most sensitive to age (Cox et al. 2016). There was one specific significant association, such that e4 carriers tended to have worse FA of the tract forceps major (fully adjusted standardised beta = −0.078, 95% CI = −0.138 to −0.018, \( P = 0.011 \). However, there were no e4 associations with MD, nor any interactions between e4 and age/age 2 on FA/MD (P value range otherwise = 0.108 to 0.994; data available upon request). We re-ran the nominally significant e4 present vs. absent association with WM hyperintensity volumes, as an e4/e4 vs. non-e4 model: this was statistically significant (fully-adjusted model standardised beta = 0.217, 95% CI = 0.066 to 0.368, \( P = 0.005 \), with the caveat that there were relatively few e4 homozygotes (\( n = 189 \). The e4 allele present vs. absent association with WM hyperintensity volumes remained significant when corrected for type 1 error with FDR (fully adjusted q-value = 0.038) but the association with tract forceps major FA did not (fully adjusted q-value >0.05).

Supplementary Table 3 shows that compared with the full UK Biobank sample (after appropriate quality controlling as described in the methods), the imaging sample here had a similar frequency of APOE e4 but was slightly less deprived (imaging Townsend mean = −2.02, SD = 2.58 vs. −1.58, SD = 2.92, \( P < 0.001 \). Table 1 shows no significant effect of e4 presence vs. absence on log WM hyperintensity volumes, although this was significant in adjusted models. The main reason for this was the statistical adjustment for age at assessment (age at assessment vs. log hyperintensity volume standardised beta in multivariate fully adjusted model = 0.06, 95% CI = 0.06 to 0.07, \( P < 0.001 \), i.e. that when age was accounted for, there was a significant e4 effect. Full final model statistics
are shown in Supplementary Table 4 and indicate that the e4/hyperintensity volume association was also independent of significant deleterious effects of male sex, diabetes, hypertension and smoking history.

Discussion

This report examined the potential association between APOE e4 genotype and brain imaging phenotypes of relevance to

Table 2  Associations between APOE e4 presence and brain MRI variables (uncorrected for type-1 error)

<table>
<thead>
<tr>
<th>Association with APOE e4 presence</th>
<th>Partially adjusted</th>
<th></th>
<th>Fully adjusted</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>b</td>
<td>Lower 95% CI</td>
<td>Upper 95% CI</td>
<td>p</td>
</tr>
<tr>
<td>gFA</td>
<td>0.034</td>
<td>0.002</td>
<td>0.025</td>
<td>0.259</td>
</tr>
<tr>
<td>gMD</td>
<td>0.027</td>
<td>0.005</td>
<td>0.056</td>
<td>0.169</td>
</tr>
<tr>
<td>Left hippocampus</td>
<td>0.005</td>
<td>0.005</td>
<td>0.005</td>
<td>0.009</td>
</tr>
<tr>
<td>Right hippocampus</td>
<td>0.005</td>
<td>0.005</td>
<td>0.005</td>
<td>0.009</td>
</tr>
<tr>
<td>Total GM (normalised)</td>
<td>0.012</td>
<td>0.005</td>
<td>0.011</td>
<td>0.007</td>
</tr>
<tr>
<td>Total WM (normalised)</td>
<td>0.029</td>
<td>0.025</td>
<td>0.036</td>
<td>0.064</td>
</tr>
<tr>
<td>Total WM hyperintensities</td>
<td>0.093</td>
<td>0.041</td>
<td>0.145</td>
<td>4 × 10⁻⁴</td>
</tr>
</tbody>
</table>

Partially adjusted: APOE e4 presence vs. absence plus 8 genetic principal components, assessment centre, genetic array, age in years and sex. Bold typeface denotes p < 0.05. Fully adjusted: (also) Townsend deprivation scores, self-reported diagnosed diabetes; hypertension; coronary heart disease, ever vs. never smoking.

GM grey matter; WM white matter; FA fractional anisotropy; MD mean diffusivity; b standardised beta; CI confidence interval; APOE apolipoprotein e; MRI magnetic resonance imaging
cognitive aging and dementia. We have previously reported on the baseline cognitive data from UK Biobank (n = 111,739) and reported generally no APOE e4*age interaction (Lyall et al. 2016b), although the sensitivity of the tests used is unclear because they were novel, very brief, and suffered a degree of floor effects (Lyall et al. 2016a). We expected the brain imaging phenotypes to be more sensitive to age-related differences conditioned on APOE genotype. In terms of addition to the literature, this study is the largest single-site study of APOE e4 genotype and brain imaging metrics which are associated with cognitive aging.

With respect to our hypotheses, there was an association between APOE e4 genotype and significantly increased WM hyperintensity volume, such that e4 carriers exhibited 0.09 SDs greater load than non-carriers, and e4/e4 homozygotes around 0.22 SDs; this reinforces findings in a smaller meta-analysis (e.g. n = 4024) (Schilling et al. 2013). One limitation of our data is that the exact mechanisms which lead to rarefaction of white matter tissue, are unclear, and may be due to different causes in different people (Wardlaw et al. 2013). The lack of a significant interaction with age provided no evidence that this effect was stronger at older ages; i.e. it was not the case that age and e4 genotype were synergistic. We found no significant associations or age interactions for APOE e4 with gFA, gMD, total GM, WM, or hippocampal volumes. The cross-sectional age range in the current sample, where most participants were aged 50 to 70 years, may limit our ability to find a significant interaction with age.

We found no significant interaction between cross-sectional older age, APOE e4 genotype and worse WM tract integrity (indexed by gFA/gMD) in around 8000 middle to older-aged adults. This is an unusually large non-consortium, single-scanner imaging genetics study, which allowed relatively high statistical power to reliably detect small effects; however we did not find any significant APOE e4 genotype-by-age interactions.

During exploratory analyses, we did find one relatively novel APOE e4 association with a specific tract FA value – namely in the tract forceps major. It is interesting that this tract was not assessed in the previously largest APOE e4/MRI study, using the Lothian Birth Cohort 1936 (n = 650) (Lyall et al. 2014). This demonstrates the importance of assessing as many specific WM tracts as can be reliably identified in imaging studies of APOE e genotype, and may indicate some differential sensitivity of some tracts (Cox et al. 2016; Lyall et al. 2014). This association did attenuate when corrected for type-1 error and may therefore be spurious. It is however worth noting that brain MRI phenotypes are usually strongly correlated (Cox et al. 2016) and generally speaking this can potentially make adjustment for type-1 overly cautious in some circumstances; independent replication in different cohorts is advised (Pike 2011).

We generally found no significant e4 genotype-by-age interactions on total GM, total WM, left or right hippocampal volumes or total WM hyperintensity volume. This is in line with some other findings; Lyall et al. (2013) reported that of six relatively large (N range 198 to 949) studies which examined APOE e4 genotype and hippocampal volumes, only two were statistically significant at P < 0.05. Generally, there is no evidence of a main effect of APOE e4 on GM volume in non-demented adults (Cherbuin et al. 2008). In terms of WM hyperintensities, one meta-analysis reported no significant association (n = 7351) however most studies were of observer-rated WH hyperintensities e.g. Fazekas scores (Paternoster et al. 2009) while another did report an association with continuous WM hyperintensity volumes (n = 8917) (Schilling et al. 2013) (standardised beta = 0.047, 95% CI = 0.0006 to 0.094, P = 0.05). Our results are therefore mostly in line with a generally null association between APOE e4 and cross-sectional brain volumes in middle age (around 60 years), but not WM hyperintensity volumes and this may suggest that at least part of APOE e4’s contribution to worse cognitive ability is via a cerebrovascular-type pathway; although the findings may also to an extent be secondary to prodromal AD.

While our findings are based on principally non-demented middle to older aged individuals, they are supportive of a vascular route from APOE e4 genotype to worse cognitive abilities. The vascular hypothesis of AD suggests significant cardiometabolic contributions to early AD neuropathology, particularly amyloid beta (Janota et al. 2016). It is possible that prodromal AD has not been fully accounted for in the current sample, although very few participants self-reported dementia at assessment.

In terms of limitations, this study tested for a cross-sectional effect of increasing age on brain WM microstructure and structural morphology; a longitudinal within-participants design may be more informative because it would minimize cohort effects associated with being born in different time periods (Anstey et al. 2003). UK Biobank will ultimately conduct longitudinal scanning in ~10,000 participants (Miller et al. 2016). The participants in the current study were of generally good health; we excluded participants who self-reported neurodegenerative diseases or those likely to affect the brain. However these diagnoses are not validated medically and we therefore cannot be certain of their accuracy; a recent analysis of self-reported rheumatoid arthritis in UK Biobank showed that only around half of participants that reported the chronic illness were on relevant medication, which puts the validity of the diagnoses into question (Siebert et al. 2016). Our analyses looked at relatively non-specific brain imaging phenotypes, as compared with for example hippocampal-subfields. Future studies will expand the range of phenotypes, as well as including a larger sample N once more UK Biobank participants have been scanned and their data released.
There may be some selection bias in the current sample, where primarily healthier older participants are likely to respond positively to invitation and attend assessment. It is also possible that this occurs across the whole sample with regards socioeconomic status, whereby more middle-class, professional people are liable to participate; we attempted to correct for this with Townsend scores however these are proxies for deprivation rather than being based on individual-level data. Generally, the rate of participants with exclusionary diseases were similar to the full UK Biobank cohort of approximately 500,000 – suggesting little bias in that regard between participants that attended baseline assessment from 2006 to 2010, vs. MRI scanning more recently. The current sample was slightly less deprived than the full UK Biobank dataset of n approximately 500,000. There may also be a degree of survival bias where the APOE e4 by age interaction is underestimated because the older people with a more deleterious effect of e4 are more likely to be missing (Heffernan et al. 2016): we saw no significant difference in e4 frequency by age group (<50; 50–59; ≥60) although there was a small but significant overall continuous effect where the e4 carriers were on average around half-a-year younger.

This report examined the effects of APOE e4 genotype on specific known substrates of worse cognitive aging however it was not totally exhaustive. For example, we did not investigate some brain phenotypes that have been reported to underlie some cognitive deficits, such as cortical thickness (Karama et al. 2014) nor did we examine structural brain metrics totally systematically and agnostically, e.g. voxel-based morphometry. Future research will take this more hypothesis-free approach in investigating APOE e4’s links to brain structure and its relevance to cognitive abilities.

Our principal finding was that APOE e4 significantly associated with increased WM hyperintensity volumes. In future, UK Biobank will include biomarker and serum lipid data. These data may be used to inform part of the causal chain from APOE genotype (a lipid transporter gene) to cognitive/brain phenotypes. While this report includes MRI and genetic data on around 10,000 participants from UK Biobank, ultimately around 100,000 will have data on these by around 2023 (Miller et al. 2016); this will permit even greater statistical power in future with which to detect such effects with greater reliability still.

Acknowledgements This research has been conducted using the UK Biobank resource; we are grateful to UK Biobank participants and research team members who collected the data, administered the data release and to the UK Biobank MRI team who processed and checked the MRI variables. This research was conducted using UK Biobank application 17689. Thanks to Prof. Cathryn Lewis and Dr. Matthew Traylor for helpful suggestions.

Funding UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council (MRC), Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. Smith is supported by an MRC Mental Health Data Pathfinder Award (MC_PoC_17217). Cox is supported by grants from the MRC (MR/M013111/1 and MR/R024065/1) and US National Institutes of Health (National Institute on Aging: R01AG054628-01A1) and the work was undertaken within the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (http://www.ccace.ed.ac.uk), part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698 and MR/K026992/1), funding from the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and MRC is gratefully acknowledged.

Compliance with ethical standards

Conflict of interest IJD is a UK Biobank participant. JPP and NS are members of the UK Biobank scientific advisory committee. None of these factors affected study conception, analysis or interpretation.

Ethical approval This study was conducted under generic approval from the NHS National Research Ethics Service (approval letter dated 17th June 2011, ref. 11/NW/0382).

Informed consent UK Biobank participants provided written consent at baseline assessment, and later at MRI: http://www.ukbiobank.ac.uk/wp-content/uploads/2011/06/Consent_form.pdf

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References


© Springer